



FemmePharma
GLOBAL HEALTHCARE, INC.

FemmePharma Global Healthcare, Inc. Announces the Divestiture of its Product for the Treatment of Endometriosis to KV Pharmaceutical Company

PRODUCT SHOWS PROMISING RESULTS IN PHASE 2 CLINICAL TRIALS

WAYNE, PA, June 15, 2005 – FemmePharma Holding Company, Inc. parent of FemmePharma Global Healthcare, Inc. announced that effective May 4, 2005 it entered into an agreement with KV Pharmaceutical Company to divest its product FP 1096 which treats the painful symptoms of endometriosis for an undisclosed amount that resulted in a significant return to its shareholders.

FemmePharma developed FP1096 using its proprietary PARDEL® technology which allows for the local regional delivery of the active ingredient directly to the region affected by endometriosis, thus minimizing the systemic exposure to the active ingredient. In the Phase 2 clinical trials conducted by FemmePharma, FP1096 demonstrated a reduction of pain associated with endometriosis and at the same time showed minimal side effects. The clinical trial results demonstrate the positive impact of FP1096 on the quality of life for women with endometriosis.

“We are eager to see this important treatment option enter the market to help alleviate the pain that endometriosis inflicts on millions of women each and every day”, commented Gerianne Tringali DiPiano, President and CEO of FemmePharma Global Healthcare, Inc.

Endometriosis is a painful chronic disease that affects 89 million women worldwide. The endometriosis market in the United States has been estimated to be \$2.5 billion. The disease occurs when endometrial tissue, or tissue resembling the lining of the uterus, develops in the pelvic region, which can cause severe pain during each menstrual cycle. The cause of endometriosis is not known and morbidity associated with this women’s disease can be considerable. Pain can be debilitating and result in loss of school and work days. Endometriosis is also the leading cause of infertility among women of reproductive age, accounting for an estimated 25% to 30% of unexplained infertility.

###